PARTAGE Method Reveals Genome Regulation in Single Approach

Why It Matters

By unifying replication timing, CNV, and gene‑expression profiling, PARTAGE offers a more comprehensive and scalable tool for cancer genomics, potentially shortening the path from discovery to clinical insight.

Key Takeaways

• PARTAGE measures replication timing, CNVs, and gene expression from one sample
• Method eliminates cell-cycle synchronization, saving time and reagents
• Results match gold‑standard Repli‑seq and RNA‑seq accuracy
• Enables cost‑effective clonal tracking and cancer genome‑instability studies

Pulse Analysis

Multi‑omics integration has become a cornerstone of modern genomics, yet most laboratories still rely on separate assays to map replication timing, copy‑number variation, and transcriptional output. This fragmented approach inflates costs, requires larger cell inputs, and complicates data alignment across platforms. PARTAGE addresses these pain points by co‑purifying DNA and nuclear RNA from the same nuclei, enabling simultaneous Repli‑seq and RNA‑seq. The workflow leverages BrdU labeling and high‑resolution FACS, eliminating the need for cell‑cycle synchronization and preserving native chromatin states, which improves the fidelity of downstream analyses.

Technical advantages of PARTAGE extend beyond convenience. The use of non‑toxic, narrow‑spectrum DNA dyes ensures precise cell‑cycle gating, while nuclear RNA enrichment captures nascent transcripts less affected by cytoplasmic turnover. By applying a multifraction Repli‑seq strategy and normalizing against G1‑purified nuclei, the method generates accurate replication‑timing heat maps and detects copy‑number alterations with sequencing depths comparable to dedicated CNV assays. Benchmarking against traditional Repli‑seq and RNA‑seq pipelines demonstrates equivalent sensitivity and specificity, confirming that the integrated protocol does not compromise data quality.

For the cancer research community, PARTAGE opens new avenues for linking replication‑timing shifts to oncogenic transcription programs and structural genome changes. The ability to monitor RT, CNV burden, and gene‑expression dysregulation in a single experiment streamlines clonal tracking and genome‑integrity screens, accelerating the identification of novel biomarkers and therapeutic targets. As large‑scale tumor atlases continue to expand, scalable, cost‑effective methods like PARTAGE will be essential for translating multi‑dimensional genomic insights into actionable clinical strategies.